Sugi Predict

Sugi Predict / Compounds / SCHEMBL1665041

SCHEMBL1665041

SCHEMBL1665041

COCCOc1cccc(C(=O)O)c1

nearest known ligand 0.73

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.73
▸ NR1H4 Q96RI1 5/20 0.60
▸ NR4A2 P43354 4/20 0.59
▸ PLA2G4B P0C869 1/20 0.58
▸ MRGPRX4 Q96LA9 1/20 0.56
▸ SMPD1 P17405 3/20 0.55
▸ PKM P14618 1/20 0.54
▸ AKR1C3 P42330 1/20 0.54
▸ NR4A1 P22736 1/20 0.54
▸ NR4A3 Q92570 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30517635 1.00 KMT2A (0.73) KMT2ANR1H4NR4A2PLA2G4BMRGPRX4
SCHEMBL6929972 0.95 KMT2A (0.68) KMT2ANR1H4NR4A2PLA2G4BMRGPRX4
SCHEMBL2934559 0.92 KMT2A (0.71) KMT2ANR1H4NR4A2PLA2G4BMRGPRX4
SCHEMBL10787479 0.91 KMT2A (0.80) KMT2ANR1H4NR4A2PLA2G4BPKM
SCHEMBL30167982 0.91 KMT2A (0.80) KMT2ANR1H4NR4A2PLA2G4BPKM
SCHEMBL28294885 0.88 L3MBTL1 (0.57) KMT2ANR1H4SMPD1
SCHEMBL6932542 0.88 KMT2A (0.75) KMT2ANR1H4NR4A2PLA2G4BMRGPRX4
SCHEMBL2868546 0.88 KMT2A (0.61) KMT2ANR1H4NR4A2PLA2G4BMRGPRX4
SCHEMBL9803295 0.88 KMT2A (0.80) KMT2ANR1H4NR4A2PLA2G4BAKR1C3
SCHEMBL10989423 0.87 MAOB (0.60) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260008788-A1 AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE SUZHOU ARK BIOPHARMACEUTICAL CO LTD (CN) 2026-01-08 — — US disclosed
EP-4596554-A1 AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE Suzhou Arkbiopharmaceutical Co., Ltd. (CN) 2025-08-06 — — EP disclosed
WO-2024067660-A1 AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE 苏州爱科百发生物医药技术有限公司 2024-04-04 — — WO disclosed
US-11866431-B2 Bicyclic compounds VIVACE THERAPEUTICS, INC. (US) 2024-01-09 — — US disclosed
US-20230061429-A1 BICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-20210380588-A1 Novel Compounds and Uses Thereof OXFORD FINANCE LLC 2021-12-09 — — US disclosed
EP-3877356-A1 BICYCLIC COMPOUNDS Vivace Therapeutics, Inc. (US) 2021-09-15 — — EP disclosed
CN-113302175-A Bicyclic compounds 维瓦斯治疗公司 2021-08-24 — — CN disclosed
US-10954244-B2 Compounds and uses thereof KALA PHARMACEUTICALS, INC. (US) 2021-03-23 — — US disclosed
US-20200157106-A1 Novel Compounds and Uses Thereof KALA BIO, Inc. 2020-05-21 — — US disclosed
US-20040014783-A1 Chemical compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2004-01-22 — — US disclosed
US-20040006080-A1 Chemical compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2004-01-08 — — US disclosed
EP-1322611-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2003-07-02 — — EP disclosed
US-6525070-B2 For therapy of chemokine (such as CCR3) or H1 mediated disease state ASTRAZENECA AB (SE) 2003-02-25 — — US disclosed
EP-1274701-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2003-01-15 — — EP disclosed
US-20020077337-A1 Chemical compounds ASTRAZENECA AB (SE) 2002-06-20 — — US disclosed
WO-2002020484-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2002-03-14 — — WO disclosed
WO-2001077101-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2001-10-18 — — WO disclosed
CN-1076694-A Novel herbicide RHONE POUIENC AGRICUITURE LTD (GB) 1993-09-29 — — CN disclosed
EP-0560483-A1 4 Benzopyl isoxazole derivatives and their use as herbicides RHONE-POULENC AGRICULTURE LTD. (GB) 1993-09-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11866431-B2 Bicyclic compounds YAP1, MYC, TEAD2 KMT2A 2062/4885NR1H4 421/4885NR4A2 924/4885
US-20020077337-A1 Chemical compounds CCR3, CCR1, CCR4 KMT2A 3084/4885NR1H4 131/4885NR4A2 1269/4885
US-20260008788-A1 AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE PDE4B, PDE4A, CYP4A11 KMT2A 1996/4885NR1H4 192/4885NR4A2 168/4885
US-20210380588-A1 Novel Compounds and Uses Thereof RB1, VEGFA, UACA KMT2A 4801/4885NR1H4 896/4885NR4A2 2186/4885
US-20200157106-A1 Novel Compounds and Uses Thereof RB1, VEGFA, UACA KMT2A 4801/4885NR1H4 896/4885NR4A2 2186/4885
US-20230061429-A1 BICYCLIC COMPOUNDS YAP1, MYC, TEAD2 KMT2A 2062/4885NR1H4 421/4885NR4A2 924/4885
US-10954244-B2 Compounds and uses thereof RB1, VEGFA, FLT4 KMT2A 4789/4885NR1H4 896/4885NR4A2 2401/4885
US-20040006080-A1 Chemical compounds CCR3, CCR1, CCR4 KMT2A 3084/4885NR1H4 131/4885NR4A2 1269/4885
US-20040014783-A1 Chemical compounds CCR3, CCR1, CCR4 KMT2A 3084/4885NR1H4 131/4885NR4A2 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.